IP Library › Granted Patent US 10,166,204
Granted Patent B2
US 10,166,204 · App. 15/954,131 · Granted Jan 1, 2019

Sphingosine kinase type 1 inhibitors and uses thereof

Inventors: Sarah Spiegel (Richmond, VA); Robert Elliot Zipkin (Wynnewood, PA); Jeffrey Kroll Adams (Fort Washington, PA)
Assignee: Enzo Therapeutics, Inc.
A61K31/135A61K31/40C07C215/28C07C217/64C07C233/18C07C323/32C07D263/06C07D295/092
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,204
App. No.
15/954,131
Granted
Jan 1, 2019
Kind
B2
Abstract

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).

Claims (24)

1. A method for treating ulcerative colitis in a patient, comprising:

administering to a patient in need of treatment for ulcerative colitis a compound having the formula

2. The method of claim 1 , wherein the administering step comprises administering to the patient the compound having the formula

3. The method of claim 2 , wherein the administering step comprises administering the hydrochloride salt of the compound to the patient.

4. A method for treating ulcerative colitis in a patient, comprising:

administering to a patient in need of treatment for ulcerative colitis a compound having the formula

wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.

5. The method of claim 4 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.

6. The method of claim 5 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring.

7. The method of claim 6 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms.

8. The method of claim 7 , wherein R is a straight carbon chain or a branched carbon chain.

9. The method of claim 8 , wherein R is a straight carbon chain.

10. A method for treating colon cancer in a patient, comprising:

administering to a patient in need of treatment for colon cancer a compound having the formula

11. The method of claim 10 , wherein the administering step comprises administering to the patient the compound having the formula

12. The method of claim 11 , wherein the administering step comprises administering the hydrochloride salt of the compound to the patient.

13. A method for treating colon cancer in a patient, comprising:

administering to a patient in need of treatment for colon cancer a compound having the formula

wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.

14. The method of claim 13 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.

15. The method of claim 14 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring.

16. The method of claim 15 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms.

17. The method of claim 16 , wherein R is a straight carbon chain or a branched carbon chain.

18. The method of claim 17 , wherein R is a straight carbon chain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: ZIPKIN, ROBERT ELLIOT; ADAMS, JEFFREY KROLL; SPIEGEL, SARAH
To: ENZO THERAPEUTICS, INC.; VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 045814/0577 →
Continuity (6)
Continuation 15181826 · Jun 14, 2016
Continuation 13649221 · Oct 11, 2012
Division 12584131 · Aug 31, 2009
Continuation In Part 12387228 · Apr 29, 2009
Provisional Application 61048638 · Apr 29, 2008
Related Publication 20180235907A1 · Aug 23, 2018